Amgen said on Monday its experimental cancer therapy significantly improved overall survival in patients with advanced ...

Amgen’s first quarter results reflected robust demand across its portfolio, with product volumes and sales increasing in both ...

Amgen and Zai Lab have reported that the Phase III FORTITUDE-101 trial, assessing bemarituzumab in combination with ...

In a detail-thin announcement, Amgen said that adding bemarituzumab to chemotherapy improved overall survival, though ...

Amgen acquired Five Prime in 2021 on the back of the phase 2 FIGHT trial of bemarituzumab, which achieved significant ...

The Dow Dow Jones Industrial Average was most recently trading 492 points higher (1.1%), as shares of Amgen Amgen Inc. and Merck Merck & Co. Inc. have contributed around 25% of the blue-chip gauge's ...

Amgen's Phase 3 trial of bemarituzumab plus chemo met its survival goal in FGFR2b+ gastric cancer, with full data expected ...

Buoyed by positive gains for shares of Amgen and Merck, the Dow Jones Industrial Average is climbing Tuesday morning. Supported by world-class markets data from Dow Jones and FactSet, and partnering ...

Back in 2021, Amgen picked up the phase 3-ready candidate in a $1.9 billion acquisition of Five Prime Therapeutics. The ...

Amgen & Zai Lab's trial shows bemarituzumab + chemo boosts survival in gastric cancer with FGFR2b. Read more here.

The Warren Buffett Indicator has climbed to 205%, the highest point ever tracked. That figure officially tops levels seen ...

US biotech major Amgen today announced the Phase III FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus ...